A5085875893- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Immune cells in cancer
- Chronic Myeloid Leukemia Treatments
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Iron Metabolism and Disorders
- Cancer Research and Treatments
- Neuroendocrine Tumor Research Advances
- Cancer Cells and Metastasis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Eosinophilic Disorders and Syndromes
- HER2/EGFR in Cancer Research
- Metabolism, Diabetes, and Cancer
- Neuroblastoma Research and Treatments
- Helicobacter pylori-related gastroenterology studies
- Lung Cancer Research Studies
- PARP inhibition in cancer therapy
- Epigenetics and DNA Methylation
- Cancer therapeutics and mechanisms
- Neutropenia and Cancer Infections
Henry Ford Hospital
2025
Emory University
2021-2024
Michigan State University
2023-2024
Henry Ford Health System
2023-2024
Emory University Hospital
2022
Winship Cancer Institute
2022
Piedmont Cancer Institute
2022
Wayne State University
2014-2021
The Barbara Ann Karmanos Cancer Institute
2018-2020
Friedrich Schiller University Jena
2016
Background Preclinical studies showed metformin reduces exhaustion of tumor-infiltrating lymphocytes and potentiates programmed cell death protein-1 (PD-1) blockade. We hypothesized that with nivolumab would elicit potent antitumor immune modulatory activity in metastatic microsatellite stable (MSS) colorectal cancer (CRC). evaluated this hypothesis a phase II study. Methods Nivolumab (480 mg) was administered intravenously every 4 weeks while (1000 given orally, two times per day following...
We conducted a phase Ib/II clinical trial to evaluate the safety, feasibility, and activity of combining pembrolizumab (anti-PD-1) with XL888 (Hsp90 inhibitor) in patients advanced colorectal cancer (CRC). hypothesized that this regimen would modulate soluble cellular immune mediators enhance outcomes. The employed 3 + open-label design, an expansion cohort at recommended II dose (RP2D) treatment-refractory, mismatch repair-proficient CRC patients. Comprehensive analyses plasma cytokines,...
Gastric adenocarcinoma is a highly aggressive disease with poor overall survival. The nature of this in part due to the high intra and inter tumoral heterogeneity also late diagnosis at presentation. Once progression occurs, treatment more difficult adaptation tumors, which acquires resistance commonly used chemotherapeutics. In report, using publicly available data sets pathway analysis, we highlight vast gastric cancer by investigating genes found be significantly perturbed. We several...
Pancreatic ductal adenocarcinoma (PDAC) remains an unmet clinical problem in urgent need of newer molecularly driven treatment modalities. Calcium signals, particularly those associated with calcium release-activated (CRAC) channels, are known to influence the development, growth, and metastasis many cancers. This is first study investigating impact CRAC channel inhibition on PDAC cell lines patient-derived tumor models. were exposed a novel inhibitor, RP4010, presence or absence standard...
Pathologic staging is crucial in colorectal cancer (CRC). Unlike the majority of solid tumors, current model does not use tumor size as a criterion. We evaluated predictive and prognostic impact primary on all stages CRC.Using National Cancer Database (NCDB), we conducted an analysis CRC patients diagnosed between 2010 2015 who underwent resection their cancer. Univariate multivariate analyses were used to identify factors, Kaplan-Meier Cox proportional hazards models for association...
Scientific research output measured by the number and quality of publications reflects productivity a certain community.To examine quantity produced Syrian institutions with particular emphasis on clinical biomedical research.Retrospective observational analysis originating from indexed Medline Science Citation Index (SciVerse) Scopus bibliographic databases.Comprehensive review literature SciVerse was conducted including data Jan 01, 1980 till February 2011 searching for authors affiliated...
Abstract Background: Pancreatic adenocarcinoma (PDAC) is an aggressive malignancy with dismal prognosis. Most patients present advanced stages. Heightened levels of serum interleukin-6 (IL-6) are associated carcinogenesis, immune suppression, and poor prognosis in PDAC. Preclinical data dual inhibition IL-6 programmed death ligand-1 (PD-L1) facilitates CD8+ T-cell migration into pancreatic tumors was effective controlling tumor growth syngeneic genetically engineered PDAC mouse models....
TPS626 Background: Interleukin-6 (IL-6) is associated with carcinogenesis, immune suppression, and poor prognosis in pancreatic adenocarcinoma (PDAC). Preclinical data demonstrated dual inhibition of IL-6 (programmed death ligand-1) PD-L1 facilitates CD8+ T cell migration into tumors was effective controlling tumor growth syngeneic genetically engineered PDAC mouse models. Siltuximab a chimeric monoclonal antibody which targets the molecule specifically spartalizumab high-affinity...
Galectin-3 plays critical roles in the adhesion, proliferation, and differentiation of tumor cells. Recent data have suggested that galectin-3 a role development hepatocellular carcinoma (HCC); however, its prognostic value has not been validated. The aim our study was to evaluate clinical patients with HCC.
Background High-risk features, such as T4 disease, bowel obstruction, poorly/undifferentiated histology, lymphovascular, perineural invasion, and <12 lymph nodes sampled, indicate poor prognosis define high-risk stage II disease in proficient mismatch repair colon cancer (CC). The prognostic role of features dMMR/MSI-H CC is unknown. Similarly, the adjuvant therapy with (≥1 feature) has not been studied prospective trials. aim this analysis National Cancer Database to evaluate value...
Abstract Background The survival impact of multi-agent (MAC) compared with single-agent (SAC) adjuvant chemotherapy (AC) in elderly patients stage III colon cancer (CC) remains controversial. aim this study was to compare outcomes MAC and SAC population utilizing the National Cancer Database (NCDB). Patients Methods aged ≥70 years pathological CC diagnosed 2004-2015 were identified NCDB. Univariate multivariable analyses conducted, Kaplan-Meier analysis Cox proportional hazard models used...
Abstract Background and Aims Non‐alcoholic steatohepatitis (NASH) is a common cause of hepatocellular carcinoma (HCC) worldwide. Emerging data suggests NASH‐induced HCC could be associated with less response to immune checkpoint inhibitor (ICI)‐based therapy. Metformin has been improved outcomes in cancers like melanoma treated ICIs, but its impact on not well defined. The purpose this study was examine the effect metformin clinical patients advanced ICIs. Methods We retrospectively analysed...
3579 Background: Panitumumab (Pmab) is a recombinant monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR) and it indicated for treatment of metastatic colorectal carcinoma (mCRC). However, objective response rates (ORR) single agent are historically about 8-11%. EGFR inhibition induces synthetic lethality with poly ADP ribose polymerase inhibitors (PARPi) such as Niraparib, by attenuating DNA repair pathways. Combining PARP has potential confer...
Over the past decade, researchers have identified and characterized diverse cell populations within tumor microenvironment of pancreatic cancer. The interplay between these cells in TME either promotes or inhibits malignant behavior cancer cells. Cancer-associated fibroblasts, previously thought to be one main subset, can now broadly subclassified into three types: inflammatory, myofibroblastic, antigen-presenting, with former latter two exerting pro-tumoral anti-tumoral functions,...
95 Background: Preclinical data suggests metformin can improve immune exhaustion of tumor infiltrating lymphocytes and potentiate the effects PD-1 blockade. By normalizing hypoxic TME, was shown to cytotoxic T cell function efficacy anti-PD-1 antibody in highly aggressive B16 melanoma MC38 colon adenocarcinoma models. Based on this preclinical rationale we conducted a phase II study with nivolumab combination treatment refractory MSS metastatic colorectal cancer (mCRC). Methods: Nivolumab...
Abstract Background: The cytokine GDF15 is overexpressed in solid malignant tumors such as colorectal, lung and urothelial cancer, where it modulates T cells, dendritic cells (DCs) myeloid-derived driving the tumor microenvironment toward an immunosuppressive, tumor-promoting state. AZD8853 a humanized immunoglobulin G1 monoclonal antibody that binds to, neutralizes, GDF15. Anti-GDF15 treatment increased cell proliferation DC activation, leading to antitumor immune response preclinical...